Corbus Pharmaceuticals (CRBP) CMO sells 3,285 shares for RSU taxes

Rhea-AI Filing Summary

Corbus Pharmaceuticals’ Chief Medical Officer Dominic Smethurst sold 3,285 shares of common stock on February 3, 2026 at a weighted average price of $8.0898 per share. The shares were sold to cover tax withholding triggered by the vesting and settlement of restricted stock units under an issuer-mandated “sell to cover” arrangement, so the sale was not discretionary. After this transaction, he beneficially owns 95,887 shares, including 86,265 unvested RSUs that remain subject to their vesting schedules.

Insider Trade Summary

Net Seller: 3,285 shares ($26,575)

Net Sell 1 txn

Insider Smethurst Dominic

Role Chief Medical Officer

Sold 3,285 shs ($27K)

Type	Security	Shares	Price	Value
Sale	Common Stock, par value $0.0001 per share	3,285	$8.0898	$27K

Holdings After Transaction: Common Stock, par value $0.0001 per share — 95,887 shares (Direct)

Footnotes (1)

1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.01 to $8.15. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This amount includes 86,265 unvested RSUs subject to each grant's vesting schedule as previously reported.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smethurst Dominic

(Last) (First) (Middle)

C/O CORBUS PHARMACEUTICALS HOLDINGS, INC

500 RIVER RIDGE DRIVE

(Street)

NORWOOD MA 02062

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Corbus Pharmaceuticals Holdings, Inc. [ CRBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	02/03/2026		S(1)		3,285	D	$8.0898(2)	95,887(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.01 to $8.15. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. This amount includes 86,265 unvested RSUs subject to each grant's vesting schedule as previously reported.

	/s/ Meghan Houghton, Attorney-in-Fact for Dominic Smethurst	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Corbus Pharmaceuticals (CRBP) disclose in this Form 4?

The filing shows Chief Medical Officer Dominic Smethurst sold 3,285 Corbus Pharmaceuticals shares on February 3, 2026. The sale was to cover tax withholding owed from vesting restricted stock units, under an issuer-mandated “sell to cover” arrangement rather than a discretionary open-market sale.

Why did the Corbus Pharmaceuticals (CRBP) CMO sell 3,285 shares?

The CMO sold 3,285 shares solely to fund tax withholding obligations from the vesting and settlement of restricted stock units. The company required these taxes be satisfied through a “sell to cover” transaction, meaning the shares were automatically sold instead of a voluntary trading decision.

At what price were the Corbus Pharmaceuticals (CRBP) shares sold in this Form 4?

The reported sale used a weighted average price of $8.0898 per share for the 3,285 shares. The transactions occurred in multiple trades within a price range from $8.01 to $8.15, and detailed trade-level pricing is available upon request from the reporting person.

How many Corbus Pharmaceuticals (CRBP) shares does the CMO own after this transaction?

After the sale, the Chief Medical Officer beneficially owns 95,887 Corbus shares directly. This total includes 86,265 unvested restricted stock units that will vest over time according to each grant’s existing vesting schedule as previously disclosed in earlier filings.

Were the Corbus Pharmaceuticals (CRBP) insider sales discretionary trades?

No, the filing states the sale was mandated by the issuer’s election to use “sell to cover” for tax withholding. Shares were automatically sold to satisfy tax liabilities from RSU vesting, so the transaction does not represent a discretionary trading decision by the reporting person.

What does the Form 4 for Corbus Pharmaceuticals (CRBP) tell investors about RSUs?

The Form 4 explains that RSU vesting triggered tax obligations settled via share sales and notes the reporting person still holds 86,265 unvested RSUs. These units remain subject to each grant’s vesting schedule, indicating a continuing equity-based compensation stake tied to future service.